499 assets in Hepatocellular Carcinoma

Therapeutic assets addressing Hepatocellular Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Nofazinlimab Hepatocellular Carcinoma	CStone Pharmaceuticals	P3	CCC (52)
NWRD06 Hepatocellular Carcinoma	Newish Technology (Beijing) Co., Ltd.	P2	CCC (52)
Phosphonic Acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]Methyl]-2,5-Dihydro-5-Oxo-1H-1,2,4-Triazol-1-Yl]- Hepatocellular Carcinoma	Guangxi Medical University	P3	CCC (52)
Piflufolastat Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	CCC (52)
sh006 Hepatocellular Carcinoma	Nanjing Sanhome Pharmaceutical, Co., Ltd.	P2/3	CCC (52)
Sitravatinib Hepatocellular Carcinoma	BeiGene	P3	CCC (52)
Sonidegib Hepatocellular Carcinoma	University of Florida	P2	CCC (52)
Spartalizumab Hepatocellular Carcinoma	SOLTI Breast Cancer Research Group	P2	CCC (52)
Trastuzumab Hepatocellular Carcinoma	Fate Therapeutics	P2	CCC (52)
Zinc Acexamate Hepatocellular Carcinoma	Hospital Universitari Vall d'Hebron Research Institute	P3	CCC (52)
b1962 Hepatocellular Carcinoma	Tasly Biopharmaceuticals Co., Ltd.	P2	CCC (51)
bb102 Hepatocellular Carcinoma	Broadenbio Ltd., Co.	P2	CCC (51)
Copanlisib Hepatocellular Carcinoma	Bayer	P2	CCC (51)
FAPI74 Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	CCC (51)
Fostrox Hepatocellular Carcinoma	CHA University	P2	CCC (51)
Immunoglobulin G1, Anti-(Human Interleukin 27) (Human Monoclonal Srf388 ?1-Chain), Disulfide With Human Monoclonal Srf388 ?-Chain, Dimer Hepatocellular Carcinoma	Coherus Oncology, Inc.	P2	CCC (51)
Ondansetron Hepatocellular Carcinoma	First Affiliated Hospital of Wenzhou Medical University	P2	CCC (51)
Pembrolizumab/Vibostolimab Coformulation Hepatocellular Carcinoma	Merck Sharp & Dohme LLC	P2	CCC (51)
Taselisib Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	CCC (51)
Tinengotinib Hepatocellular Carcinoma	Akeso	P2	CCC (51)
Idarubicin Hydrochloride For Hepatocellular Carcinoma	Zhongda Hospital	P2/3	CCC (50)
Memantine Hepatocellular Carcinoma	Inova Health Care Services	P2/3	CCC (50)
Obinutuzumab Hepatocellular Carcinoma	Simcha IL-18, Inc.	P1/2	CCC (50)
Rulonilimab Hepatocellular Carcinoma	Shandong New Time Pharmaceutical Co., LTD	P2/3	CCC (50)
scg101 Hepatocellular Carcinoma	SCG Cell Therapy Pte. Ltd.	P1/2	CCC (50)
Fluoromisonidazole Hepatocellular Carcinoma	Emory University	P2	CCC (49)
IMA970A Hepatocellular Carcinoma	National Cancer Institute, Naples	P1/2	CCC (49)
Tcr-T Cells Hepatocellular Carcinoma	Lion TCR Pte. Ltd.	P1/2	CCC (49)
Triadeno Vaccine Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	CCC (49)
1.0% ip-001 for Hepatocellular Carcinoma	Robert C. Martin	P2	CCC (48)
Adbelimumab Hepatocellular Carcinoma	Fujian Cancer Hospital	P2	CCC (48)
Atilizumab Hepatocellular Carcinoma	Abbisko Therapeutics Co, Ltd	P2	CCC (48)
Atirizumab Hepatocellular Carcinoma	Second Affiliated Hospital, School of Medicine, Zhejiang University	P2	CCC (48)
Autologous Dendritic Cell/Tumor Antigen, Adcta Hepatocellular Carcinoma	Chang Gung Memorial Hospital	P2	CCC (48)
Avatrombopag Hepatocellular Carcinoma	Second Affiliated Hospital of Guangzhou Medical University	P2	CCC (48)
Candonilimab Hepatocellular Carcinoma	Shi Ming	P2	CCC (48)
Casdozokitug Hepatocellular Carcinoma	Coherus Oncology, Inc.	P2	CCC (48)
Domvanalimab Hepatocellular Carcinoma	University of Texas Southwestern Medical Center	P2	CCC (48)
Dpx-Survivac Hepatocellular Carcinoma	ImmunoVaccine Technologies, Inc. (IMV Inc.)	P2	CCC (48)
e7386 Hepatocellular Carcinoma	Eisai Inc.	P1/2	CCC (48)
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) Hepatocellular Carcinoma	H. Lee Moffitt Cancer Center and Research Institute	P2	CCC (48)
exl01 Hepatocellular Carcinoma	Center Eugene Marquis	P2	CCC (48)
Ezurpimtrostat Hepatocellular Carcinoma	University Hospital, Grenoble	P2	CCC (48)
Foslinanib Hepatocellular Carcinoma	TaiRx, Inc.	P2	CCC (48)
Fruquintinib Hepatocellular Carcinoma	Sun Yat-sen University	P2	CCC (48)
Gecacitinib Hepatocellular Carcinoma	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (48)
H-Gamma1 Heavy Chain Homo Sapiens (1-447) [Vh (Homo Sapiens Ighv4-5901 (99.0%) -(Ighd) -Ighj302 (93.3%) T125>I (114), Cdr-Imgt [8.7.11] (26-33.51-57.96-106)) (1-117) -Homo Sapiens Ighg101, G1M17,1 Ch1 K120, Ch3 D12, L14, 9-G1V21 Ch2 Y15.1, T16, E18 (Ch1 K120 (214) (118-215), Hinge 1-15 (216-230), Ch2 M15.1>Y (252), S16>T (254), T18>E (256) (231-340), Ch3 D12 (356), L14 (358) (341-445), Chs (446-447)) (118-447)], (220-214')-Disulfide With L-Kappa Light Chain Homo Sapiens (1'-214') [V-Kappa (Homo Sapiens Igkv3-1101 (96.8%) -Igkj401 (100%), Cdr-Imgt [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo Sapiens Igkc01 (100%) Km3 A45.1, V101 (Ckappa A45.1 (153'), V101 (191')) (108'-214')]; Dimer (226-226'':229-229'')-Bisdisulfide, Produced In A Cell Line Derived From Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa Hepatocellular Carcinoma	Kineta Inc.	P1/2	CCC (48)
js007 Hepatocellular Carcinoma	Shanghai Junshi Bioscience Co., Ltd.	P2	CCC (48)
js207 Hepatocellular Carcinoma	Shanghai Junshi Bioscience Co., Ltd.	P2	CCC (48)
kd6001 Hepatocellular Carcinoma	Shanghai Kanda Biotechnology Co., Ltd.	P1/2	CCC (48)

Showing 201 to 250 of 499 assets

PreviousPage 5 of 10Next